---
figid: PMC9935926__41392_2023_1332_Fig5_HTML
figtitle: 'Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic
  interventions'
organisms:
- Cricetulus griseus
- Mus musculus
- Rattus norvegicus
- Escherichia coli SCD1
- Escherichia coli FBP1
- Clostridium novyi NT
- Escherichia coli
- Danio rerio
- Salmonella enterica subsp. enterica serovar Typhimurium
- Homo sapiens
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Cricetulus griseus
- Homo sapiens
pmcid: PMC9935926
filename: 41392_2023_1332_Fig5_HTML.jpg
figlink: /pmc/articles/PMC9935926/figure/Fig5/
number: F5
caption: Hypoxia remodels CTL immune effect. HIF-1α in CTL is upgraded by TCR-PKC
  and Ca2+/calcineurin, PI3K/mTOR, NF-κB, NF-κB, JAK-STAT3, MAPK pathway. Deletion
  of pVHL impaired HIF-1α degradation. HIF-1α and HIF-1β dimerization stimulates downstream
  factor expression, such as perforin, IFN-γ, TNF-α, which can enhance the antitumor
  efficacy of CTL. However, some experiments elaborate the opposite results. Hypoxia
  inhibits the expression of IFN-γ, TNF-α, granzyme B, IL-2, perforin and NKG2D, while
  promoting PD-L1,PD-1 and CTLA-4 expression. CTL increases glucose uptake via GLUT1,
  which is metabolized to lactate by glycolytic enzymes PK and LDH. Lactate acidifies
  the TME, which inhibits CTL activation
papertitle: 'Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic
  interventions.'
reftext: Zhou Chen, et al. Signal Transduct Target Ther. 2023;8:70.
year: '2023'
doi: 10.1038/s41392-023-01332-8
journal_title: Signal Transduction and Targeted Therapy
journal_nlm_ta: Signal Transduct Target Ther
publisher_name: Nature Publishing Group UK
keywords: Cancer metabolism | Cancer microenvironment
automl_pathway: 0.9472848
figid_alias: PMC9935926__F5
figtype: Figure
redirect_from: /figures/PMC9935926__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9935926__41392_2023_1332_Fig5_HTML.html
  '@type': Dataset
  description: Hypoxia remodels CTL immune effect. HIF-1α in CTL is upgraded by TCR-PKC
    and Ca2+/calcineurin, PI3K/mTOR, NF-κB, NF-κB, JAK-STAT3, MAPK pathway. Deletion
    of pVHL impaired HIF-1α degradation. HIF-1α and HIF-1β dimerization stimulates
    downstream factor expression, such as perforin, IFN-γ, TNF-α, which can enhance
    the antitumor efficacy of CTL. However, some experiments elaborate the opposite
    results. Hypoxia inhibits the expression of IFN-γ, TNF-α, granzyme B, IL-2, perforin
    and NKG2D, while promoting PD-L1,PD-1 and CTLA-4 expression. CTL increases glucose
    uptake via GLUT1, which is metabolized to lactate by glycolytic enzymes PK and
    LDH. Lactate acidifies the TME, which inhibits CTL activation
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Trav6-3
  - Tnf
  - Pik3r1
  - Slc1a3
  - Slc2a1
  - Nfkb1
  - Stat3
  - Mtor
  - Hif1a
  - Vhl
  - pk
  - Cd274
  - Ctla4
  - Pdcd1
  - Il2
  - Klrk1
  - Prkcg
  - Pik3cg
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - TNF
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SLC2A1
  - NFKB1
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STAT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MTOR
  - HIF1A
  - VHL
  - LDHA
  - LDHB
  - LDHC
  - SETD2
  - ARNT
  - CD274
  - CTLA4
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - IL2
  - KLRK1
  - Lactate
  - TNF-a
  - Glucose
  - Pyruvate
---
